Lv1
30 积分 2021-06-04 加入
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Monoclonal Gammopathy of Undetermined Significance
2个月前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
2个月前
已完结
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
6个月前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
7个月前
已完结
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
7个月前
已完结
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance
7个月前
已完结
Artificial Intelligence and Chromothripsis
7个月前
已完结
BCL2 inhibition for multiple myeloma and AL amyloidosis
8个月前
已完结
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
